Cancer Vaccine R&D Makes Strides With Better Endpoints, Patient Selection
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As cancer vaccine and immunotherapy developers try to get past the difficulties of recent years, they are looking to improve their chances for success by identifying the correct cancer types and settings to best respond to a specific vaccine and then choosing more meaningful endpoints for clinical trials.